By Kuldip K. Ambastha
Novavax, Inc. (NVAX), a clinical-stage vaccine company, had its stock price fall by -17.2% per share on Thursday, June 9, 2022. (See past coverage if needed: “What Caught Our Attention in the Investment World? – Week of December 27-31, 2021; By Kuldip K. Ambastha.”) In 1Q2022, earnings per share plus total revenues did not surpass Wall Street’s consensus estimates, and furthermore Wall Street has now adjusted its future expectations downwards. In the USA, the Vaccines and Related Biological Products Advisory Committee of the Food and Drug Administration (FDA) has voted to give emergency-use authorization (EUA) to Novavax’s COVID-19 vaccine NVX-CoV2373. However, the FDA has also stated that changes in Novavax’s production processes need to be reviewed further, and this negative regulatory news dominated anything positive seen for Novavax in the past trading week.
Keywords – Novavax, Inc., Novavax, NVAX, clinical-stage, vaccine, NVX-CoV2373, COVID-19, coronavirus, pandemic, 1Q2022, earnings per share, revenues, emergency-use authorization, EUA, United States of America, United States, USA, Food and Drug Administration, FDA, regulation.
Disclosure – The principals and clients of Ambastha Financial LLC have no positions in NVAX.
Disclaimer – No recommendations are being made via this post. Past performance is not an indicator of future performance. As an investor, you should do your own research and seek professional advice from a Registered Investment Adviser (RIA). You can lose money by investing in stocks and other instruments. Ambastha Financial LLC does not assume any responsibility (legal or otherwise) for any losses that may occur as a result of actions taken based on this post. All content copyrighted © 2022 – Ambastha Financial LLC.